ACP
DYN icon

Acuta Capital Partners’s Dyne Therapeutics DYN Stock Holding History

Acuta Capital Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-46,200
Closed -$1.66M – 43
2024
Q3 		$1.66M Sell
46,200
-166,300
-78% -$6.62M 1.34% 23
2024
Q2 		$7.5M Buy
212,500
+28,000
+15% +$814K 6.32% 4
2024
Q1 		$5.24M Buy
184,500
+36,664
+25% +$829K 3.4% 11
2023
Q4 		$1.97M Buy
147,836
+1,336
+0.9% +$13.1K 1.11% 25
2023
Q3 		$1.31M Buy
146,500
+73,500
+101% +$792K 0.88% 31
2023
Q2 		$821K Buy
+73,000
New +$861K 0.56% 31

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acuta Capital Partners's DYN Position: Q4 2024 in Review

Acuta Capital Partners sold out of Dyne Therapeutics (DYN) in Q4 2024, closing a stake of 46,200 shares — an estimated $1.66M sold.

Acuta Capital Partners first reported a position in DYN in Q2 2023 and held it in 6 quarters. The position peaked at $7.5M in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q4 2024.

  • Acuta Capital Partners reported no remaining Dyne Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 46,200 Dyne Therapeutics shares in Q4 2024, an estimated $1.66M.
  • Acuta Capital Partners first reported a position in Dyne Therapeutics in Q2 2023 and held it in 6 quarters.
  • Acuta Capital Partners's Dyne Therapeutics position peaked at $7.5M in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2024.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.